CD274 and small cell lung carcinoma: Pembrolizumab first showed efficacy among the PD-L1-positive SCLC patients of the Keynote 028 study, with promising primary end point ORR (33.3%, 95% CI: 15.6–55.3%) and secondary end points (median DOR, median PFS, and median OS).